Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
A&G Pharmaceutical
A&G Pharmaceutical, Celltrion sign bioprocess development, manufacturing deal
July 4th, 2006
A&G Pharmaceutical, Inc., and Celltrion, Inc., have entered into an agreement for clinical production of a novel A&G theranostic monoclonal antibody. Celltrion will perform bioprocess development, scale-up, and cGMP manufacturing and provide all clinical materials to support toxicology studies as well as phase I and phase II U.S. clinical studies on A&G's anti-GP88 monoclonal antibody. The anti-GP88 antibody is currently in preclinical development by A&G as a cancer therapeutic. The agreement provides Celltrion exclusive commercialization rights in Asia, including Japan, to anti-GP88 oncology therapies. In return, A&G will receive clinical materials...
Source: Pharma Law Weekly (2006-07-04)
|
